wao logo

 

WAO News & Notes - April
WAO新闻和纪要-四月

Medical Journal Review
WAO Now: What's New in the World of WAO
And In Other News . . .
医学杂志回顾
今日WAOWAO领域新进展
其他新闻


For Information about WAO Travel Grants to WAC 2007 in Bangkok, click here
有关
2007年度世界变态反应大会(曼谷)WAO差旅费补助的信息,点击这里
World Allergy Organization (WAO) Announces

世界变态反应组织(
WAO)通告

WAO-Schering-Plough Corporation (SPC) &
WAO-European Academy of Allergology and Clinical Immunology (EAACI)
TRAVEL GRANTS

WAO-
先灵葆雅有限公司 (SPC) 以及
WAO-
欧洲变态反应与临床免疫学会(EAACI)
差旅费补助

World Allergy Congress 2007, 2-6 December, Bangkok, Thailand
2007年度世界变态反应大会, 20071226日,泰国曼谷

DEADLINE: 5 July 2007
截止日期: 200775

The World Allergy Organization (WAO), in partnerships with Schering-Plough Corporation (SPC) and the European Academy of Allergology and Clinical Immunology (EAACI), announces the WAO-SPC and WAO-EAACI Travel Grants for young scientists to attend WAOs World Allergy Congress (WAC) in Bangkok, Thailand , 2-6 December 2007.
世界变态反应组织(WAO)与先灵葆雅有限公司(SPC)和欧洲变态反应与临床免疫学会(EAACI)合作,为了资助年轻科学工作者能参加在泰国曼谷 20071226日期间举办的2007年度世界变态反应大会,特设立 WAO-SPCWAO-EAACI差旅费补助项目。

Applicants for travel grants must meet the following criteria:
申请差旅费必须符合以下条件:

  1. The applicant must be within five (5) years of his/her latest degree. 
  2. The applicant must submit an abstract. The abstract must be accepted for either oral or poster presentation at the Congress. Please visit the abstract submission website to submit your abstract. Only electronic submissions of abstracts are being accepted.
  1. 申请者毕业取得学位后的工作时限必须不满5 
  2. 申请者必须递交一份摘要。该摘要必须为大会所接受(或者口头形式或者以壁报形式发表)。请登录 摘要递交网站 递交您的摘要。仅接受以电子文档形式递交的摘要。

Travel grants are available to reduce personal costs involved in attending the Congress. They are not intended to cover the recipient’s total travel and accommodation costs.
差旅费补助可以用于降低与参加大会相关的个人开销。但它并非是对获得者所有旅费和食宿费用的全额报销。

Monetary awards will be given based on the recipient’s geographical location.
货币给予形式将基于接受者所在地理位置。

In addition to the monetary award, the Congress registration fee will be waived for award recipients. There will also be a luncheon in recognition of this and other travel awards, at which you will have the chance to meet other awardees and many renowned allergists.
除了在货币形式的补偿,奖学金获得者还将获得减免大会注册费。大会还将为本奖学金和其他差旅奖学金获得者举办午餐会,届时您将有机会见到其他差旅奖学金获得者以及众多变态反应知名专家。

To apply for a WAO-SPC / WAO-EAACI Travel Grant to attend the WAC 2007, complete the Travel Grant Application and attach the appropriate supporting materials. The application and supporting materials must be received by 5 July 2007.  Please either fax (+1 414 276 3349) or email (congress@worldallergy.org) your application (if emailing, please note “Travel Grant Application - <FULL NAME>” in the subject line). 
如果您计划申请有关2007年度世界变态反应大会的WAO-SPC / WAO-EAACI差旅补助,请填写差旅费补助申请并附上适当的辅助材料。申请和辅助材料必须在 200775前寄达。投递申请的方式:传真(+1 414 276 3349)或电子邮件(congress@worldallergy.org)。(如果使用电子邮件,请在主题部分注明“差旅费补助申请-<全名>”)。

For Travel Grant Application Form, click here
有关差旅费补助的申请表格,请点击这里

Applications for travel grants will be reviewed in August at the time of the Abstract Review Meeting. Applicants will be notified in September 2007 regarding the status of their travel grant application. 
有关差旅费补助的所有申请将在八月份的摘要评审会议上进行评审。所有申请者的结果将在20079月予以通报。

For questions regarding travel grants, please contact the WAO Secretariat:
如果对于差旅费补助方面您仍有疑问,请与WAO秘书处联系:

World Allergy Organization
世界变态反应组织
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel
电话: +1 414 276 1791
Fax
传真: +1 414 276 3349
E-mail
电子邮件: congress@worldallergy.org
Web site
网站: www.worldallergy.org


Medical Journal Reviews
医学杂志回顾

Prof. Richard F. Lockey, MD, WAO Web Editor-in-Chief, reviewed premier medical journal articles for practicing allergists.
Richard F. Lockey
教授,医学博士,WAO网站主编,他为在业的变态反应科医生回顾了医学杂志的一些重要文章。

1. SALMETEROL (S) AND FLUTICASONE PROPIONATE (FP) AND SURVIVAL IN CHRONIC OBSTRUCTIVE PLUMONARY DISEASE (COPD)
This is a randomized, double-blind trial comparing S 50 µg plus FP 500 µg in a single inhaler two times daily with placebo, S 50 µg alone, or FP 500 µg alone for 3 yrs to treat COPD. The primary outcome was death from any cause. Secondary outcomes included frequency of exacerbation, spirometric values and health status. 6,112 patients were included, and 875 died within 3 yrs, 12.6% in the combination–therapy group, 15.2% in the placebo group, 13.5% in the S group, and 16.0% in the FP group, corresponding to a difference of 2.6 percentage points or a reduction in the risk of death of 17.5% (P=0.052). S alone or FP alone did not differ significantly from placebo. Compared with placebo, the combination regimen reduced annual exacerbation rates from 1.13 to 0.85 and improved health status and spirometric values (P<0.001 for all comparisons with placebo). Pneumonia as an adverse event was higher among patients receiving medications containing FP (19.6% in the combination-therapy group and 18.3% in the F group) vs. placebo (12.3%, P<0.001 for comparisons between these treatments and placebo). The reduction in deaths from all causes did not reach statistical significance; however, there are significant benefits in other outcomes with the combined therapy. Editor’s comment: Combination-therapy reduced annual exacerbation rates and improved health status and spirometric values (secondary outcomes) but had no statistical effect on mortality (primary outcome).
Calverley PMA, et al. N Engl J Med 2007; 356: 775. Editorial, Rabe KF. N Engl J Med 2007; 356; 851.
译文:
1.
沙美特罗(S)联合丙酸氟替卡松(FP)治疗慢性阻塞性肺疾病(COPD
本研究随机双盲,观察COPD患者使用以下治疗方法3年的效果:使用单一吸入装置每日两次沙美特罗(S50 µg联合丙酸氟替卡松(FP500 µg ,安慰剂,单用沙美特罗(S50 µg,或者单用丙酸氟替卡松(FP500 µg 。主要观测指标:每组中任何原因导致的死亡。次要观测指标包括:急性发作的频率,肺功能以及健康状况。研究一共纳入6,112位患者,3年内共有875位死亡,其中联合治疗组12.6%,安慰剂组15.2%,沙美特罗组13.5% ,丙酸氟替卡松组16.0%,联合治疗组比安慰剂组减少2.6个百分点,也就是说该组死亡风险降低了17.5%P=0.052)。与安慰剂组相比,沙美特罗组和丙酸氟替卡松组均未见显著变化。与安慰剂组相比,联合治疗组每年急性发作率下降(由1.13减为0.85),同时健康状况以及肺功能均有所改善,所有指标的P值均小于0.001。如果患者接受的治疗方案中含丙酸氟替卡松,则发现肺炎这一不良事件的发生率较高:联合治疗组19.6%,丙酸氟替卡松组18.3%,而安慰剂组12.3%,前两组和安慰剂组相比P<0.001。所有治疗组中死亡率的减少未达到统计学显著性差异;但是联合治疗组在其它指标上都显示出了优越性。编者按:联合治疗可以减少COPD患者每年急性发作率,改善健康状况和肺功能(次要指标),但是对死亡率(主要指标)没有带来具统计学意义的效果。 Calverley PMA, et al. N Engl J Med 2007; 356: 775. Editorial, Rabe KF. N Engl J Med 2007; 356; 851.

2. VANCOMYCIN-INDUCED IMMUNE THROMBOCYTOPENIA
Vancomycin-dependent, platelet-reactive IgG or IgM antibodies were identified in 34 patients suspected of having vancomycin-induced thrombocytopenia. Clinical follow-up information on 29 patients revealed a mean nadir platelet count of 13,600 per mm3 and severe bleeding in 10 patients (34%). Platelet levels returned to baseline in all 26 surviving patients when vancomycin was stopped. Vancomycin-dependent antibodies were not found in 25 controls given vancomycin without thrombocytopenia. The authors conclude that severe bleeding occurs in vancomycin-induced immune thrombocytopenia and the diagnosis can be confirmed by the detection of vancomycin-dependent antiplatelet antibodies. Editor’s comment: Add vancomycin to the list of drug-induced thrombocytopenia. Von Drygalski A, et al. N Engl J Med 2007; 356: 904. Editorial, Warkentin TE. N Engl J Med 2007; 356: 891.
译文:
2.
万古霉素诱导的免疫性血小板减少症
研究者34例疑似患有万古霉素诱导的血小板减少症患者体内检测到万古霉素依赖性、血小板活性IgG抗体或IgM抗体。通过对其中29例患者进行临床随访,结果显示平均最低血小板计数为13,600/mm3,其中有10例患者发生严重出血(34%)。当停止使用万古霉素后,存活的26例患者体内的血小板水平能够恢复到基线水平。在对照组,25例使用万古霉素并且未出现血小板减少症的患者体内未检测到万古霉素依赖性抗体。作者总结指出:万古霉素诱导的血小板减少症患者可以发生严重出血,对本病可以通过检测万古霉素依赖性抗血小板抗体进行确诊。编者按:万古霉素也可以诱导产生药物性血小板减少症。Von Drygalski A, et al. N Engl J Med 2007; 356: 904. Editorial, Warkentin TE. N Engl J Med 2007; 356: 891.

3. A BRIEF HISTORY OF TH17, THE FIRSTS MAJOR REVISION IN THE TH1/TH2 HYPOTHESIS OF T CELL-MEDIATED TISSUE DAMAGE
This author reviews the evolution of several hypotheses which dominated thinking in cell-to-cell regulation and interaction and the pathogenesis of disease. First was the concept of T-helper and T-suppressor cells which was replaced by the concept that cytokines produced by the TH1 cells could negatively regulate the function of TH2 cells and vice versa. The TH1/TH2 hypothesis is being replaced by newer data which indicate that a pathway named TH17 is now credited for causing and sustaining tissue damage in diverse situations such as organ-specific autoimmunity in the brain, heart, synovium and intestines, allergic disorders of the lung and skin, and microbial infections of the intestines and nervous system. It is likely to become established that no single cytokine can regulate a vital process like tissue damage and that it is a constellation of cytokines, tuned in concert, which ultimately produces a complex phenotype like “tissue damage” or “recovery from tissue damage”. Editor’s comment: This is a very lucid article summarizing the newest information on T-helper cell differentiation and regulation. Must reading for everyone. Steinman L. Nature Medicine 2007; 13: 139.
译文:
3. TH17
简史,这是有关阐述T细胞介导组织损伤的TH1/TH2假说的首次重大修改
当前学术界存在若干阐述细胞间调控、相互作用以及疾病发生机制的假说,本文作者对这些假说的新进展进行了回顾。首先,我们来看有关T辅助细胞和T抑制细胞的概念,该概念目前被取代为:Th1细胞产生的细胞因子可以对Th2细胞的功能产生负调节作用,反之亦然。而TH1/TH2假说目前也正被越来越多的最新资料所动摇,近新获得的资料显示:一条全新的途径,Th17,被认为触发并持续了多个部位的组织损伤,例如脑组织、心脏、滑膜和小肠的器官特异性自身免疫反应,肺脏和皮肤的过敏性疾病,小肠和神经系统的微生物感染。人们逐渐达成共识:类似组织损伤的重要过程并不是由单一某种细胞因子所能调节的,该过程是由众多细胞因子共同作用的结果,正是这些细胞因子的相互作用,最终产生了诸如“组织损伤”、“组织损伤后修复”等复杂的现象。编者按:这篇文章架构清晰,利用最新的资料对T辅助细胞的分化和调节做了总结,的确值得一读。Steinman L. Nature Medicine 2007; 13: 139.

4. META-ANALYSIS: INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN CRITICALLY ILL ADULT PATIENTS WITH SEPSIS
All randomized controlled trials of critically ill adults with sepsis, severe sepsis or septic shock who received IVIG or placebo or no intervention were reviewed. 20 trials (n=2621) met eligibility criteria and were analyzed. IVIG was associated with an overall survival benefit (RR, 0.74 [95% CI, 0.62 to 0.89) compared with placebo or no intervention. The authors suggest that a large randomized, controlled trial of IVIG therapy be performed because of the methodological limitations of the current literature review. Editor’s comment: IVIG seems to be helpful in adult patients with sepsis, but a large controlled trial is necessary. Turgeon AF, et al. Ann Intern Med 2007; 146: 193.
译文:
4.
荟萃分析:静脉注射免疫球蛋白(IVIG)治疗成人败血症危重患者
作者收集了所有关于败血症、重症败血症或者毒性休克的随机对照试验,对这些成人危重患者是否接受静脉注射免疫球蛋白(IVIG)治疗进行了回顾分析。共有20份试验(n=2621)符合研究标准予以收录分析。与安慰剂或者未加干预治疗相比,研究显示IVIG有益于总生存率RR0.74 95% CI, 0.62 to 0.89〕)。作者建议:为了弥补本研究在方法学上的局限性,需要对IVIG进行一项大型随机、对照试验。编者按:静脉注射免疫球蛋白似乎有益于成人败血症患者的治疗,但这一观点需要进行大型对照试验予以证实。Turgeon AF, et al. Ann Intern Med 2007; 146: 193.

5. CLINICAL TRIAL OF LOW-DOSE THEOPHYLLINE (T) AND MONTELUKAST(M) IN PATIENTS WITH POORLY CONTROLLED ASTHMA (A)
This is a randomized, double-masked, placebo-controlled trial of 489 subjects with poorly controlled A randomly assigned to placebo, T (300 mg/d), or M (10 mg/d). Participants were monitored for 24 wk to measure rate of episodes of poor A control (EPACs) defined by decreased peak flow (PEF), increased β-agonist use, increased oral corticosteroid (CS) use, or unscheduled health care visits. Results show there was no significant difference in EPACs compared with placebo: low-dose T, 4.9 (95% CI, 3.6-6.7; not significant); M, 4.0 (95% CI, 3.0-5.4; not significant) and placebo, 4.9 (95% CI, 3.8-6.4). M and T caused small improvements in prebronchodilator FEV1 of borderline significance. Either treatment improved A symptoms or QOL. In subjects not receiving inhaled CS, additional T significantly (p<0.002) improved asthma control and symptoms as well as lung function. The authors conclude that neither M nor low-dose T lowered EPACs in patients with poorly controlled A despite improved lung function. For patients not using inhaled CS, low-dose T improves A symptom control more than M or placebo and provides a safe and low-cost alternative A treatment. Editor’s comment: T is still a good cost-effective drug to use for A. The American Lung Association Asthma Clinical Research Centers. Am J Respir Crit Care Med 2007; 175: 235.
译文:
5.
临床试验:使用低剂量茶碱(T)和孟鲁司特(M)治疗哮喘(A)未控制患者
该试验随机、双盲、安慰剂对照,共纳入了489例哮喘未控制患者,所有入组患者随机分为安慰剂组,茶碱治疗组(300 mg/天),以及孟鲁司特治疗组(10 mg/天)。对所有入组患者进行监测24周并衡量哮喘未控制率(EPACs,哮喘未控制的定义为:呼气峰流速(PEF)下降,β受体激动剂使用次数增加,口服皮质激素使用次数增加,以及非预约就诊的次数。研究结果显示,与安慰剂组相比,各治疗组的EPACs无统计学差异:低剂量茶碱治疗组4.995% CI3.6-6.7;无显著性意义);孟鲁司特治疗组4.095% CI3.0-5.4;无显著性意义),安慰剂组4.995% CI3.8-6.4)。孟鲁司特治疗组和低剂量茶碱治疗组可以小幅度改善舒张前FEV1,该结果具有临界显著性意义。两组治疗组均可以改善哮喘症状和生活质量(QOL)。对于那些没有使用吸入皮质激素的患者,辅助使用茶碱可以显著改善(p<0.002)哮喘控制状况,改善症状和肺功能。作者总结:尽管孟鲁司特和低剂量茶碱可以改善哮喘未控制患者的肺功能,但两种方法均不能降低EPACs。对于那些没有使用吸入皮质激素的患者,与孟鲁司特和安慰剂相比,低剂量茶碱可以更好地改善哮喘症状,该方法安全、价格低廉,可作为哮喘控制的备选方法之一。编者按:对于哮喘的治疗,茶碱依然是一个高性价比的选择。The American Lung Association Asthma Clinical Research Centers. Am J Respir Crit Care Med 2007; 175: 235.

6. COMBINATION THERAPY WITH A LONG-ACTING β-AGONIST AND A LEUKOTRIENE ANTAGONIST IN MODERATE ASTHMA
192 subjects (12 to 65 yr) with moderate asthma were enrolled in a randomized, placebo-controlled study comparing the clinical efficacy of treatment for 14 wks with montelukast (M) and salmeterol (S) compared to beclomethasone (B) and S. The primary outcome was time to treatment failure. M and S was inferior to B and S as judged by protection against asthma treatment failures (p =0.0008), lung function ( 26 L/min difference in A.M. PEF, P = 0.011), asthma control score (0.22 difference in Asthma Control Questionnaire score, p = 0.038), and markers of inflammation and airway reactivity. The authors conclude that M and S should not be substituted for inhaled corticosteroid (ICS) and LABA. Editor’s comment: ICS (with or without a long-acting β-agonist) remains the first treatment of choice for moderate asthma in this age group. Deykin A, et al. Am J Respir Crit Care Med 2007; 175: 228.
译文:
6.
联合使用长效β受体激动剂和白三烯受体拮抗剂治疗中度哮喘患者
本研究为随机、安慰剂对照试验,共纳入192例(12 65岁)中度哮喘患者,目的是通过14周治疗比较以下两种方法的临床疗效差异:孟鲁司特(M)联合沙美特罗(S),以及倍氯米松(B)联合沙美特罗(S)。主要指标为治疗后再次哮喘发作的时间。倍氯米松联合沙美特罗在以下方面优于孟鲁司特联合沙美特罗:治疗对哮喘发作的保护作用(p =0.0008),肺功能(清晨PEF差值 26 L/minP = 0.011),哮喘控制评分(哮喘控制问卷评分差值0.22分,p = 0.038),炎性标志物以及气道反应性。作者总结:孟鲁司特联合沙美特罗不能取代吸入皮质激素(ICS)联合LABA编者按:吸入皮质激素(联合或未联合使用长效β受体激动剂)仍然是该年龄组中度哮喘患者的一线治疗方案。Deykin A, et al. Am J Respir Crit Care Med 2007; 175: 228.

7. LIVE ATTENUATED (LAIV) VS. INACTIVATED INFLUENZA VACCINE (IIV) IN INFANTS AND YOUNG CHILDREN
Approximately, 8,000 children, 6 to 59 months of age, without a recent episode of wheezing illness or severe asthma, were randomly assigned in a 1:1 ratio to receive either cold-adapted trivalent IAIV intranasally or trivalent IIV in a double-blind manner. Influenza-like illness was monitored with cultures throughout the 2004-05 influenza season. There were 54.9% fewer cases of cultured-confirmed influenza in the group that received LAIV than in the group that received IIV (153 vs. 338 cases, P<0.001). Among previously unvaccinated children, wheezing within 42 days of the administration of dose 1 was more common with LAIV than IIV, primarily among children 6 to 11 months of age (P=0.076). Rates of hospitalization for any cause during the 180 days were higher among the LAIV recipients who were 6 to 11 months of age (6.1%) vs. the recipients of IIV in this age group (2.6%, P=0.002). The authors conclude that LAIV had significantly better efficacy than IIV and should be a highly effective, safe vaccine for children 12 to 59 months of age without a history of asthma or wheezing. Editor’s comment: LAIV is more effective than IIV but should not be used in children with asthma. Belshe RB, et al. N Engl J Med 2007; 356: 685. Editorial, Cox NJ, Bridges CB. N Engl J Med 2007; 356: 729.
译文:
7.
对婴幼儿和儿童中使用流感减毒活疫苗(LAIV)和流感灭活疫苗(IIV)的区别
研究共纳入大约8,000 659月龄的儿童,近期无喘息性疾病或重症哮喘发作史,这些儿童随机按1:1分为两组,双盲给予鼻内冷适应三价流感减毒活疫苗或者三价流感灭活疫苗。研究人员对这些儿童在2004-2005年度流感好发季节出现的流感样疾病予以监测,同时进行病毒培养。与接受流感灭活疫苗接种的儿童相比,经病毒培养验证,流感减毒活疫苗接种组发生流感的病例总数减少54.9%153 vs. 338 例次,P<0.001)。监测对即往未接受过免疫接种的儿童在给予第一次接种后42天内喘息的发生情况,结果发现LAIV接种组中喘息发生次数多于IIV接种组,在611月龄的儿童组尤为明显(P=0.076)。在611月龄的儿童组中比较180天内总住院率,LAIV接种组(6.1%)多于IIV接种组(2.6%P=0.002)。作者总结:LAIV效果明显优于IIV,对于那些即往无喘息和哮喘病史的1259月龄儿童, LAIV不失为高效、安全的疫苗。编者按:流感减毒活疫苗(LAIV)效果优于流感灭活疫苗(IIVLAIV,但不适用于哮喘患儿。Belshe RB, et al. N Engl J Med 2007; 356: 685. Editorial, Cox NJ, Bridges CB. N Engl J Med 2007; 356: 729.

8. DETECTION OF AN ALERGEN IN DOG DANDER THAT CROSS-REACTS WITH THE MAJOR CAT ALLERGEN, Fel d 1
These authors took a recombinant (rFel d 1) with the same immunologic properties as natural Fel d 1 and used it for quantitative (CAP) IgE competition experiments performed with sera obtained from 36 cat-allergic patients. They found that a Fel d 1 cross-reactive dog allergen was characterized by one- and two-dimensional immunoblotting using rFel d1 for IgE inhibition experiments and with monospecific, polyclonal rabbit anti-recombinant Fel d 1 antibodies. In 25% of Fel d 1-reactive cat-allergic patients, more than 50% inhibition of IgE reactivity to dog allergens was achieved with rFel d 1. A Fel d 1 cross-reactive 20 kDa allergen with a pI of approximately 3.4 was detected in dander extracts of several different dog breeds. They conclude that a Fel d 1-like allergen in dog dander extracts exist and may be responsible for double positivity to cat and dog in serology, and provide evidence that dog and cat dander, besides Can f 3/Fel d 2 (albumin) and perhaps Fel d 4 (lipocalin), contain other cross-reactive antigens. Editor’s comment: This is additional evidence that cat and dog allergens cross-react. Reininger R, et al. Clin Exp Allergy 2007; 37: 116.
译文:
8.
在狗皮屑中发现一种与主要猫变应原,Fel d 1,具有交叉反应的变应原成份
文章作者们收集了36例猫过敏患者的血清,使用具有与天然Fel d 1相同免疫学特性的重组变应原(rFel d 1)进行定量IgE竞争实验(CAP)。研究中发现了一种与Fel d 1存在交叉反应的狗变应原,该变应原可以通过使用rFel d1IgE抑制实验,单一特异性、多克隆兔抗rFel d1抗体进行单向和双向免疫印迹加以证实。 25%Fel d 1反应的猫过敏患者中,使用rFel d 1可获得对狗变应原IgE反应性超过50%的抑制率。与Fel d 1交叉反应性20 kDa变应原的pI大约为3.4 ,可以在若干种系狗的皮屑浸液中检测到。作者总结:狗皮屑浸液中存在Fel d 1样变应原,这可能造成血清学上对猫和狗出现双重阳性反应,这进一步指出,除了Can f 3/Fel d 2(白蛋白)以及可能的Fel d 4(脂质运载蛋白,lipocalin),猫和狗的皮屑中还存在其他的交叉反应性变应原。编者按:这篇文章进一步证实猫和狗的变应原之间存在交叉反应。Reininger R, et al. Clin Exp Allergy 2007; 37: 116.

9. A HUMAN INTERLEUKIN-12/23 MONOCLONAL ANTIBODY (MA) FOR THE TREATMENT OF PSORIASIS
320 patients (age > 18 yr) with moderate-to-severe plaque psoriasis underwent randomization in this double-blind placebo-controlled trial for treatment with the MA or placebo. 64 patients were randomly assigned to each group. There was at least 75% improvement in the psoriasis area-and-severity index at wk 12 (the primary end point) in 53% of patients who received 45 mg of the MA vs. placebo. Higher doses achieved even better results (P < 0.001). There was no statistical difference in adverse or serious adverse events. The authors conclude that this study demonstrates the therapeutic efficacy of a MA for psoriasis and provides further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiology of this disease. Editor’s comment: Aberrant type I immune responses are linked to the pathogenesis of psoriasis and interleukin-12 and IL-23 seem to be the appropriate therapeutic targets. Krueger GG, et al. N Engl J Med 2007; 356: 580.
译文:
9.
应用人白介素-12/23单克隆抗体(MA)治疗银屑病
本试验随机双盲、安慰剂对照,共有320例中重度斑块型银屑病患者(年龄 > 18岁)随机接受白介素-12/23单克隆抗体(MA)或安慰剂治疗。每组随机分到64例患者。与安慰剂组相比,53%接受45mg白介素-12/23单克隆抗体(MA)治疗的患者在银屑病面积和严重程度指数上在治疗12周时(主要观察终点)改善程度超过75%。更高的治疗剂量可以获得更好的结果P < 0.001)。研究显示在不良事件和严重不良事件上未见统计学差异。作者总结:该研究证实MA对治疗银屑病具有治疗效果,同时对考察白介素-12/23 p40细胞因子在银屑病病理生理学中扮演的角色提供了更多的证据编者按:I型免疫应答异常与银屑病的发病机制相关,白介素-12和白介素-23有可能成为合适的治疗靶位。 Krueger GG, et al. N Engl J Med 2007; 356: 580.

10. NFkB IN BREAST CANCER (BC) CELLS PROMOTES OSTEOLYTIC BONE METASTASIS BY INDUCING OSTEOCLASTOGENESIS VIA GMCSF
Reviewed by Gary Hellermann, Ph.D.
Persons with BC have a high incidence of bone metastases because BC cells have an affinity for bone but also because they secrete factors that stimulate osteoclasts which are responsible for bone resorption. These authors reasoned that since the transcription factor NF-kappaB (nuclear factor-kappa B) regulates genes involved in tumor invasion and metastasis, it may also be involved in the osteolytic bone metastases seen in some BC patients. They found that a cancer cell line highly metastatic for bone had significantly higher NF-kappaB activity than one that was weakly metastatic. Using mice as a model they showed that blocking NF-kappaB reduced the size and number of osteolytic lesions, in some cases preventing them completely. A potential connection with NF-kappaB was made when it was discovered that the increased activity of NF-kappaB correlated with an increase in GM-CSF (granulocyte macrophage-colony stimulating factor) which stimulates osteoclast differentiation. Editor’s comment: NF-kappaB is a ubiquitous proinflammatory factor and this study demonstrates that anti-NF-kappaB treatment may prove to be effective in preventing cancer metastasis. Park et al. Nature Med 2007; 13: 62.
译文:
10.
乳腺癌(BC)细胞中的NFkB 可以通过粒细胞巨噬细胞-集落刺激因子(GMCSF)诱导的破骨细胞促使产生溶骨性骨转移
本文由Gary Hellermann, Ph.D.回顾
患有乳腺癌的人群发生骨转移的几率高,这是因为乳腺癌细胞具有针对骨骼的亲和性,同时癌细胞可以分泌因子刺激破骨细胞造成骨吸收。支持作者观点的理由包括 NF-kappaB(核因子-κB )转录因子调控基因参与了肿瘤的侵袭和转移,它还可能参与了某些乳腺癌患者溶骨性骨转移。研究发现如果某一癌细胞株较其他癌细胞株具有更强的骨转移性,则该株癌细胞NF-kappaB 活性明显增强。使用小鼠模型的研究显示阻断NF-kappaB可以减少溶骨性损害的大小和数目,在某些患病个体甚至可以起到完全预防作用。研究还发现了一个潜在的联系:NF-kappaB活性增强和GMCSF(粒细胞巨噬细胞-集落刺激因子)上升相关,GMCSF可以刺激破骨细胞的分化。编者按:NF-kappaB是一种广泛存在的前炎性因子,本研究证实抗NF-kappaB治疗可以有效预防癌细胞转移。Park et al. Nature Med 2007; 13: 62.



WAO Now: What's New in the World of WAO

今日WAOWAO领域新进展

seminars and conferencesMay 2007 Seminars & Conferences Placement
2007
5月研讨会和会议安排

6th Colombian Congress of Allergy, Asthma and Immunology
第六届哥伦比亚变态反应,哮喘和免疫学全国会议
May 24 - 27, 2007
2007
524-27
Medellin, Colombia
麦德林,哥伦比亚
WAO Invited Lecturer WAO
受邀讲者:
Joaquin Sastre


gloriaSpanish Version of Anaphylaxis Now Available!
《严重过敏反应》西班牙文版本正在发放中

WAO extends its sincere gratitude to Dr. Mario Sanchez Borges for translating into Spanish the GLORIA module on Anaphylaxis. For the Spanish Anaphylaxis module, click here.
WAO
由衷感谢Dr. Mario Sanchez Borges 为大家将GLORIA中的《严重过敏反应》单元翻译为西班牙文版本。如果您需要下载,请点击这里。

2007 May GLORIA Placements
2007
5GLORIA安排

Finger Lakes Allergy Society
May 5, 2007
W. Henrietta, NY, USA
五指湖区变态反应学会
200755
W. Henrietta, NY, USA
US GLORIA Faculty
美国GLORIA教员:
Ira Finegold
Presentations
主讲内容:
Module 2: Allergic Conjunctivitis变应性结膜炎
Module 4: Immunotherapy
免疫治疗

Long Island Allergy & Asthma Society
May 8, 2007
Woodbury, NY, USA
长岛变态反应和哮喘学会
200758
Woodbury, NY, USA
US GLORIA Faculty
美国GLORIA教员:
Ira Finegold
Presentation
主讲内容:
Module 2: Allergic Conjunctivitis变应性结膜炎

African International Conference on Immunity
26 -30 May 2007
Victoria Falls, Zimbabwe
非洲免疫学国际会议
2007526 -30
Victoria Falls, Zimbabwe
International GLORIA Faculty
国际GLORIA教员:
Cassim Motala
Presentations
主讲内容:
Module 3: Allergic Emergencies急诊变态反应学
Module 6: Food Allergy
食物过敏

GLORIA is supported through unrestricted educational grants from:
GLORIA
得到以下公司非限制性教育资助的支持

alcon

dey

dyax & genzyme

nutricia  shs

schering-plough


wafWAF Materials Available WAF资料提供中

"A Global Perspective on Genetics, the Environment and Allergy
有关基因学,环境学和变态反应学的全球性展望
WAF presenter materials and audio recordings from the recent AAAAI Annual Meeting are now available for download on the WAF web page.
最近AAAAI年会上WAF讲者的资料和音频拷贝目前可在WAF网站上下载得到

You Are Invited to Attend
邀请您参加

WAF Symposium: Immune Tolerance
WAF
座谈会:免疫耐受
XXVI EAACI Congress
Tuesday, 12 June 2007, 8:30 - 10:00 
Göteborg Convention Centre, Room K2-K3
Göteborg, Sweden

Chairs主席
Michael A. Kaliner, United States
Anthony J. Frew, United Kingdom

Concepts in tolerance induction诱导耐受相关概念
Dale Umetsu, United States

Modulation of IgE-related diseases in children儿童IgE相关性疾病的调节
Patrick Holt, Australia

Can omalizumab synergize immunotherapy? Omalizumab是否可以用来协同免疫治疗?
Thomas Casale, United States

World Allergy Forum is supported through an unrestricted educational grant from
世界变态反应论坛得到以下公司非限制性教育资助
novartis

WAO Conversations
WAO
会话
Two new interviews with experts are now available on the Web site. To listen to Dr. Bill Solomon speak on "Pollen and Mold Aerobiology" and Dr. Gerald Gleich share his knowledge on "Hypereosinophilia and Eosinophilia Disease," click here.
目前网站提供两份最新专家访谈记录。请点击这里聆听Dr. Bill Solomon主讲的“花粉和真菌大气生物学”以及Dr. Gerald Gleich主讲的“嗜酸性粒细胞增多症”。

Call for Applications接受申请中

  • WAO Short-Term Research Fellowship 2007 Applications

    The World Allergy Organization (WAO) offers three Short-Term Research Fellowships, to commence in the latter half of 2007, to support junior allergists to visit a center of their choice to learn a research technique. The expected duration of each attachment is 2-3 weeks. WAO will contribute up to a maximum of $2,500 USD, to include travel and accommodations, for each Short-Term Fellowship.

    Priority will be given to junior clinicians within five years of award of the most recent professional degree, who are specializing in allergy and who are affiliated to an academic department or clinical institute. Applicants must be current members of a WAO member society.

    The Short-Term Fellowships will be applied to a project which meets one of the WAO Research Priorities:
    • Genetic factors involved in the development of allergic disease and response to treatment
    • Allergen characterization and standardization
    • Clinical and basic studies in allergy and asthma


Application forms may be downloaded here

Applications must be received by WAO head office not later than 31 May 2007

WAO短期科研奖学金2007年度申请

世界变态反应组织(WAO)在2007年下半年开始提供三项短期科研奖学金以资助初年变态反 应医师前往他们所向往的医学中心进修并学习科研技术。进修持续时间以23周为宜。WAO将会为每位奖学金获得者资助最高2500美元的奖学金,包括旅行费用和食宿费用。
     
奖学金优先授予那些在近5年内获得专业学位的初年临床医师,其专业为变态反应,并且隶属于医学院相关科室或临床研究院。申请者必须是目前WAO成员学会的会员。
     
短期科研奖学金的申请目的必须符合以下WAO科研优先项目之一:

l                参与变应性疾病发病及其治疗反应的遗传学因素

l                变应原的鉴定和标准化

l                过敏性鼻炎和哮喘的临床及基础研究

申请表可以从此处下载:链接
申请必须在 2007531送达WAO秘书处

  • The WAO Henning Løwenstein Research Award 2007

    The WAO Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. WAO and ALK-Abelló will present the award at the World Allergy Congress in Bangkok, 2-6 December 2007.

    The winner will receive EURO 20,000 together with a travel grant to attend the World Allergy Congress.

    alk-abelloFor application guidelines, visit http://www.alk.abello.com/ and click on "The WAO Henning Løwenstein Research Award."

    Deadline: 30 June 2007

    WAO 2007年度Henning Løwenstein科研奖
    WAO Henning Løwenstein 科研奖每2年颁发一次,将授予在变态反应领域做出卓越贡献的年轻科学家。WAOALK公司将在2007122-6日曼谷召开的世界变态反应大会上向获得者颁发本次奖项。
    科研奖获得者将获得20,000欧元奖励,同时将被资助参加本次世界变态反应大会
    访问这里 http://www.alk-abello.com/ 并点击"The WAO Henning Løwenstein 科研奖"即可获得申请指南
    截止日期: 2007630

Short-Term Research Fellowship 2006 Report

This month we post the report from the WAO 2006 Short-Term Research Fellowship awarded to Dr. Daniel Potaczek from the Jagiellonian University School of Medicine, Cracow, Poland . Dr. Potaczek visited the Atopy (Allergy) Research Center, Juntendo University School of Medicine, Japan to learn new research techniques for his study "The Genetic variability of alpha chain of high-affinity IgE receptor gene and its expression". To read a report of the Fellowship, click here.

2006年度短期奖学金报告
本月我们将发布2006年度短期奖学金获得者Dr. Daniel Potaczek完成的告,Dr. Daniel Potaczek来自波兰克拉科夫(Cracow的加格罗林(Jagiellonian)大学医学院。Dr. Daniel Potaczek在日本Juntendo 大学医学院变态反应中心的进行了访问学习,期间为完成他自己的科研题目“高亲和性IgE受体基因alpha链的基因多态性及其表达”学习了必要的技术。请点击这里阅读该奖学金报告。


esp latin americaEmerging Societies Meeting - Cancun, Mexico

WAO's first Emerging Societies Meeting (ESM) of 2007 will take place during the LXI National Congress of Clinical Immunology and Allergy, 27-30 June 2007 in Cancun, Mexico . The ESM is intended as a follow-up to the ESM that was held in Latin America in 2006 and will include representatives from Honduras, Guatemala, Cuba, El Salvador, Nicaragua and Martinique. This meeting is jointly funded by the American College of Allergy, Asthma and Immunology, the Mexican College of Allergy, Asthma and Clinical Immunology and the World Allergy Organization.

For more information on the Mexican College of Allergy, Asthma and Clinical Immunology’s meeting 27-30 June 2007, click here.

新兴学会的会议-墨西哥坎昆

WAO2007年度的第一次新兴学会会议(ESM)将于2007627-30日在墨西哥坎昆的临床免疫和变态反应全国大会期间召开。本次大会作为2006年在拉丁美洲召开ESM的延续,将会有来自洪都拉斯、危地马拉、古巴、萨尔瓦多、尼加拉瓜和马提尼克等国的代表参加。这次会议将由美国变态反应、哮喘和免疫学会(ACAAI)、墨西哥变态反应、哮喘和临床免疫学会以及世界变态反应组织共同资助举办。

如果需要有关墨西哥变态反应,哮喘和临床免疫学学院在2007627-30会议的更多信息,请点击这里

Sign up for Online Journal Subscription -

WAO and Hogrefe & Huber Publishers are offering a limited number of free online subscriptions to Allergy & Clinical Immunology International - Journal of the World Allergy Organization for members in developing countries. If you are interested in receiving a complimentary, online subscription, please send an e-mail to info@worldallergy.org, noting "Free Journal Subscription" in the subject line, with the following details:

First name
Last (Family) name
Postal address
City, State/Province and postal code
Country
E-mail address
Name of Member Society

线杂志订阅申请-

WAOHogrefe & Huber出版公司现为发展中国家的会员提供有限数量的《Allergy & Clinical Immunology International - Journal of the World Allergy Organization免费在线订阅服务。如果您希望得到这份杂志的免费赠阅的电子版,请给我们发送e-mailinfo@worldallergy.org,注意在信件的主题栏写“Free Journal Subscription”,并详细注明以下资料:


姓氏
邮政地址
市,州/省和邮政编码
国家
E-mail
地址
成员学会的名称


And In Other News 其他新闻

Urticaria Guideline Published
荨麻疹指南业已出版
The British Society for Allergy & Clinical Immunologys (BSACI) Urticaria Guideline was recently published by Blackwell Publishing in Clinical & Experimental Allergy. To read the full text, click here.
英国变态反应和临床免疫学会(BSACI)近期由Blackwell Publishing in Clinical & Experimental Allergy出版了有关荨麻疹的指南。如需阅读全文,请点击这里。

Dr. Allan Kaplan, WAO Guest Editor, reviewed the BSACI’s Urticaria Guidelines and made the following comments:
Dr. Allan Kaplan
WAO客座编辑,为大家回顾了英国变态反应和临床免疫学会制定的荨麻疹指南,并做了以下评注:

The published guidelines for the manuscript of chronic urticaria and angioedema by The British Society of Allergy and Clinical Immunology (BSACI) are excellent. The guidelines are evidence based, where possible, and offer an informative and practical approach to the disorder.

The areas that I would offer some caution in interpretation are as follows:

P. 6 – The guidelines acknowledge that urticaria and angioedema cause stress and also indicate that the reverse is recognized i.e. that psychologic stress can trigger or aggravate urticaria. One article regarding a possible mechanism with upregulation of corticotrophin-releasing hormone is offered. Nevertheless stress as a trigger of urticaria is more likely to be a myth and a higher steroid receptor level in the skin should improve urticaria.

P. 8 – Two studies assert that 20% of chronic urticaria patients remain symptomatic after 10 years. Assessment of the last 2000 such patients by Dr. Allen Kaplan suggests a figure closer to 2%.

P. 12 – Studies of sedation with first generation antihistaminics have never been done with urticaria/angioedema patients. Thus the subjects have no hives, no swelling, and no itch. Sedation and performance in chronic urticaria patients may not be normal to start with; round-the-clock doses of first generation antihistaminics are often effective, and if employment of these agents (e.g. Hydroxazine or Diphenhydramine) are steroid sparing or obviate the need for cyclosporine, their use may in-fact be an important step between giving up on antihistaminics and employment of more toxic agents.

P. 12 – Tranexamic acid may have some efficacy for angioedema (other than HAE where it is documented to be an effect approach), but inhibiting the conversion of plasminogen to plasmin does not affect production of bradykinin.

这份由英国变态反应和临床免疫学会撰写的有关慢性荨麻疹和血管神经性水肿的指南非常出色。该指南的制定基于循证医学,为该类疾病的治疗提供了丰富的实践信息。
为方便大家的理解,我在这里为大家作一些提示:
6页:本指南提出荨麻疹和血管神经性水肿可以使患者产生压力,并指出反之亦然,例如,心理上的压力可以触发荨麻疹或者使其加重。有一篇文章指出该类疾病可能的发病机制与促肾上腺皮质激素释放激素的上调有关。然而,压力触发荨麻疹听起来更是荒诞的事情,皮肤如果具有更高的激素受体水平会对荨麻疹病情有改善。
8页:有两份研究指出发病10年后仍有20%的慢性荨麻疹患者存在症状。但是,Dr. Allen Kaplan经过对将近2000名此类患者评估后认为这一数字仅大约2%。
12页:有关第一代抗组胺药在荨麻疹/血管神经性水肿患者中镇静作用的相关研究尚未完成。治疗目的包括无荨麻疹,无肿胀,无痒感。在治疗初期,慢性荨麻疹患者的中枢镇静程度和操作能力可能不正常;给予24小时足够剂量的第一代抗组胺药往往是有效的,如果使用这些药物(例如盐酸羟或苯海拉明)可以避免使用皮质激素或者环霉素,在放弃抗组胺药物、使用毒性更强的药物之前,应用第一代抗组胺药确是一个重要步骤。
12页:虽然使用止血环可能对血管神经性水肿具有一定疗效(止血环酸被证实是治疗HAE有效方法),但是抑制纤溶酶原向纤溶酶的转化并不能影响缓激肽的产生。

Two Allergy Book Reviews
两本变态反应学书评

Title: Problem-based immunology书名:以问题为中心学习免疫学
Reginald M. Gorczynski and Jacqueline Stanley
ISBN: 1-4160-2416-6

List price: $34.95 USD
Available from: Elsevier
定价:34.95美元
订购网址:Elsevier

Reviewer书评作者:
Dr Jane Peake MBBS, FRACP, DTM&H
University of Queensland, Herston, Queensland, Australia

Description:
In few areas of medicine has the scientific understanding of underlying pathological processes expanded as quickly as it has in the area of immunology. This makes it difficult for medical students and clinicians to keep abreast of these findings and in particular to grasp their clinical relevance. This textbook is designed to provide "up-to-date" understanding in immunology, both the basic concepts and clinical applications. Case scenarios are used to provide relevance and to increase interest and illustrate the broad spectrum of clinical immunology disorders.
描述:
在医学领域很少有学科像免疫学这样对其病理过程的科学认识进展如此迅猛。这种情况使医学生和临床医生难以及时掌握这些新发现,尤其难以掌握这些进展的临床意义。这本教科书撰写目的在于为读者提供“最新的”免疫学知识,包括免疫学基本概念及其在临床的应用。本书提供的病例部分举例恰当,提高了阅读趣味性,为读者举例说明了众多临床免疫疾病。

Purpose:
The purpose of this textbook is to cover the basic science of immunology and using the problem-based approach provides the bridge with clinical medicine. Each section presents clinical case studies to demonstrate the practical relevance of immunology knowledge in diagnosing a variety of complex clinical disorders.
目的:
书涵盖了基础免疫学部分,并使用以问题为中心的学习方式将其与临床医学连接在一起。书中每部分均列出了相关临床病例研究,从而说明了免疫学知识在诊断各种疑难临床疾患过程中的实践意义。

Audience:
This book is designed for medical students and postgraduate students wanting to learn more about clinical immunology. It may also be of interest to those teaching these students as it provides problems and suggested group discussion topics, which can be used to stimulate teaching.
读者:
本书面向那些希望了解更多临床免疫学知识的医学生和医学研究生。本书也可以用于医学生的教学工作,由于书中提供了许多问题和建议小组讨论的题目,使用本书可以起到激励教学的作用。

Features:
There is a section on each major area in the field of clinical immunology – immunodeficiency, hypersensitivity, autoimmunity, tumour immunology, transplantation and immunisation. In each section there is an overview of the main concepts and then a number of relevant case studies. Each of the case studies starts with a clinical vignette and then poses a number of questions for group discussion. The case is then further explored with analysis of the family history, laboratory investigations, differential diagnosis and, as relevant, there may be further explanation regarding investigations, laboratory result interpretation, therapy or underlying disease process and aetiology. An interesting and unique addition to this book is the final section on psychoneuroimmunobiology, which explores the concept that the immune system is influenced by non-immunological physiological systems and the interplay between “mind” and “body”.
特色:
本书对临床免疫学的每个重要领域都安排了章节加以介绍,包括:免疫功能缺陷,超敏反应,自身免疫,肿瘤免疫学,移植和免疫。在每个章节里都含有对主要概念的概述,并安排了多个相关病例研究。每份病例研究均以临床简介作为开端,然后提出若干问题供小组讨论。随后,每份病例均从以下方面展开:相关家族病史、实验室检查以及鉴别诊断,随后还可能对有关病史调查、实验室检查结果、相关治疗以及潜在疾病进程和病因方面进行剖析。本书最后一章内容独特、有趣,该章内容围绕精神神经免疫学,认为免疫系统受非免疫性生理系统影响,也就是“精神”和“肉体”之间相互影响。

Assessment:
Problem-based immunology provides an excellent basic textbook for medical students and postgraduate students in clinical immunology. Students often have difficulty understanding both the complex science that underpins immunology and the clinical relevance of what they are learning. The design of the book stimulates the student into thinking about the scientific concepts and the cases provide clinical relevance and interest. If used as designed, by starting with the initial discussion questions before proceeding with the case, the student will be engaged in a way that they will want to continue to read more. In the developed world allergic disease is becoming an increasing problem with rapid increases in the incidence of food allergy, allergic rhinitis and eczema. The hypersensitivity section would have benefited from having cases that explored these important topics. A further reading section at the end of each case or section would have provided resources for students whose interest has been piqued and was unfortunately only available for the psychoneuroimmunobiology section.
评估:
这本免疫学教科书的设计模式以问题为中心,对于医学生和医学研究生来说,是一本有关临床免疫学领域的优秀教科书。面对免疫学相关复杂的自然科学同时试图弄懂所学内容的临床意义,医学生往往会遇到极大的困难。本书的设计思路是鼓励医学生思考所涉及的科学概念,书中提供的案例可以帮助学生掌握所学知识的临床意义并激发他们的学习兴趣。如果能依照当初的设计使用本书,也就是在开始学习病例前先了解需要讨论的问题,将会吸引医学生产生进一步学习的动力。在发达国家,变应性疾病正成为一个日益严重的问题,包括发病率正迅猛增加的食物过敏、过敏性鼻炎以及湿疹。学习超敏反应相关章节将有助于掌握这些重要领域的相关知识。在每份病例和章节后面,本书还安排了可以深入阅读的内容,以便某些感兴趣的医学生进一步学习,但美中不足的是这种补充仅在“精神神经免疫学”这一章里提供。

Title: Kendigs Disorders of the Respiratory Tract in Children书名:Kendig氏儿童呼吸道疾病学
Editors: Chernick, Boat and Wilmott, Bush

List Price: $249.00 USD
Available from: Elsevier
定价:249.00美元
订购网址:Elsevier

Reviewer书评作者:
Peter van Asperen MD FRACP
Head, Department of Respiratory Medicine, The Children’s Hospital at Westmead &
Macintosh Professor of Paediatric Respiratory Medicine, University of Sydney, Australia .

Description:
The 7th Edition of this internationally respected "bible of pediatric pulmonology", first published in 1967, has been dedicated to the memory of Dr Edwin Kendig, the founding editor who was also involved in all previous editions. It covers this broad subject in a logical sequence commencing with a section on "General Considerations" (including chapters on normal lung development and physiology as well as clinical assessment) and proceeds through various infectious and non-infectious disorders of the respiratory tract as well as diseases with a prominent respiratory component including immune mediated and immune deficient disorders. This is the first edition to contain a separate section on "Asthma" including chapters on the epidemiology and immunopathogenesis of asthma, asthma in the pre-school years and in older children, and the influence of upper airway disease on the lower airway. This section is complemented by other chapters in the “General Considerations” section including the biology and assessment of airway inflammation, and drug administration by aerosol in children.
描述:
本书为《Kendig氏儿童呼吸道疾病学》的第七版,该书长期来在国际上被推崇为“儿科肺脏学圣经”,其首次出版在1967年,本书的命名是为了纪念Edwin Kendig博士,他既是本书的创刊编辑又参与过所有早期版本的编撰。本书内容涵盖广泛,排列清晰,本书以“总论”作为起始章节(其中包括正常肺脏的发育,肺脏生理学以及相关临床评估),随后对各种呼吸道传染性和非传染性疾病以及涉及呼吸系统的疾病进行了阐述,包括免疫介导疾病和免疫缺陷疾病。本版书中第一次设立了有关“支气管哮喘”的单独章节,包括哮喘流行病学,免疫机制,学龄前儿童和少儿哮喘,以及上呼吸道疾病对下呼吸道的影响。此外,“总论”中还辅助安排了其他一些章节,包括生物学、气道炎症的评估、气溶胶给药方式在儿童中的应用。

Purpose:
The book is designed to provide a comprehensive reference text on both common and rarer paediatric respiratory diseases as well a scientific understanding of normal pulmonary function and how it might be affected by these diseases.
目的:
本书的设计是希望能为读者在以下方面提供全面的参考文献:儿科呼吸系统常见疾病及罕见病,科学地理解正常肺功能以及肺功能如何受到这些疾病的影响。

Audience:
Although primarily designed as a textbook for practising paediatric respiratory physicians and intensivists as well as trainees in these paediatric subspecialties, it also serves as a useful resource for all paediatricians and trainees, including paediatric allergists.
读者:
本书撰写的初衷是为儿科呼吸内科及重症医疗领域的执业医生和实习生服务,但它同时也可以为所有儿科医生和实习生,包括儿科变态反应医生所使用。

Features:
This latest edition has been extensively revised to incorporate the large body of new knowledge that has become available since the last edition in 1998. The authors have been carefully chosen as experts in their subject and represent views from both sides of the Atlantic as well as the Asia-Pacific. All the chapters are well set out and illustrated, are easy to read and contain a mixture of scientific and practical information with either up-to-date references or a suggested reading list. This edition also contains a series of colour plates which appear at the beginning of the book but are clearly referenced to individual chapters.
特色:
由于第六版出版于1998年,在这期间涌出大量的新知识促使编者对这本最新版做了大量的修订。本书的作者都是从大西洋两岸和亚太地区精挑细选出来具有代表性的专家。本书所有章节组织清晰,易于阅读,包含了大量的科研和实践信息,同时列出了最新参考目录或者推荐阅读清单。本版还包含了一系列彩图,不但见于书的前言部分,也为后面的章节所索引。

Assessment:
This has been and remains one of the relatively few comprehensive textbooks on paediatric respiratory disorders and with its updated material will continue to serve as an important resource for its intended audience. Like all textbooks some of the information will rapidly date but much of it will continue to be relevant until the next revision. In the section on Asthma, the information provided is generally consistent with current understanding and management approaches in paediatric asthma although the latter predominantly reflects North American management, which is not surprising given the authorship of these chapters. I would recommend this book to anyone seeking information on respiratory issues in children.

评估:
这本书长期以来一直是为数不多的儿科呼吸系统疾病综合教科书之一,经过本版的更新,它将继续为读者发挥重要作用。和所有教科书一样,虽然某部分信息更新迅速,但大部分相对固定,会维持到下次再版修订。在有关支气管哮喘的章节中,由于撰写作者来自北美,所以在哮喘的治疗方法上主要反映的是北美模式,但总体来说,书中所提供资料还是与当前对儿科哮喘的认识和治疗方法相一致的。对那些希望获得有关儿童呼吸道疾病方面信息的读者,我推荐阅读本书。

Find more allergy book reviews on the WAO Website here.
WAO
网站上其它的变态反应学书评见此处

The World Allergy Organization's mission is to build a global alliance of allergy societies to advance excellence in clinical care, research, education and training. Visit us on the Web at http://www.worldallergy.org/
世界变态反应组织的使命是建立一个全球性的变态反应学会联盟,不断推动临床、科研、教学与培训工作的进步。欢迎您浏览我们的网站: http://www.worldallergy.org/

World Allergy Organization (WAO)
Secretariat
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
Email: info@worldallergy.org
世界变态反应组织(WAO)秘书处
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202-3823
电子信箱:info@worldallergy.org

You have received this message because you are a member of a WAO Member Society, you have subscribed for the monthly e-letter or had previous contact with the World Allergy Organization. If you would prefer not to receive further messages from WAO, please reply to this message with REMOVE in the subject line.
您因如下原因收到此次通讯:您是世界变态反应协会会员,或者您曾向世界变态反应协会订阅过电子月刊,或者您以前曾与世界变态反应协会进行过有关联系。如果您不希望继续收到来自世界变态反应协会的信息,请以删除为主题回复此邮件。

Made possible through an unrestricted educational grant from Novartis.